Abbott picks top execs for AbbVie spinoff

Abbott Labs ($ABT) is sticking with the cast of players the healthcare giant knows to run its planned pharma spinoff, AbbVie. With Abbott pharma boss Richard Gonzalez already slotted for the CEO job, the company made the following AbbVie roster decisions: John Leonard, head of pharma R&D at Abbott, will have the same job at the spinoff; William Chase, a vice president of licensing and acquisitions at Abbott, will be stepping up into the role of CFO at AbbVie; Laura Schumacher will transition from general counsel at Abbott to the same job at the new pharma group; Carlos Alban, Abbott's senior vice president of pharma products and global ops, will go to work doing the same job for AbbVie; and Timothy Richmond, a divisional vice president of compensation and benefits at Abbott, will ascend to the role of chief human resources officer. The spinoff is expected to take place later this year. Article

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.